- $86.52bn
- $136.85bn
- $357.78bn
- 77
- 93
- 67
- 93
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 8.03 | ||
| PEG Ratio (f) | 0.7 | ||
| EPS Growth (f) | 12.99% | ||
| Dividend Yield (f) | 3.69% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.13 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 8.32 | ||
| Price to Sales | 0.24 | ||
| EV to EBITDA | 7.54 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 8.06% | ||
| Return on Equity | 11.28% | ||
| Operating Margin | 3.84% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 256,776 | 268,706 | 292,111 | 322,467 | 357,776 | 370,811.25 | 392,684.96 | 12.95% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +74.48 | +14.48 | +16.25 | +8.05 | -8.27 | +14.15 | +10.45 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
CVS Health Corporation is a health solutions company. The Company operates in four segments: Health Care Benefits, Health Services, Pharmacy & Consumer Wellness, and Corporate/Other. Its Health Care Benefits segment offer a range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, medical management capabilities, Medicare Advantage and Medicare supplement plans, and Medicaid health care management services. Its Health Services segment provides a full range of pharmacy benefit management solutions, delivers health care services in its medical clinics, virtually, and in the home, and offers provider enablement solutions. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations, provides ancillary pharmacy services, including pharmacy patient care programs, diagnostic testing and vaccination administration.
Directors
- David Dorman NEC (67)
- Karen Lynch PRE (58)
- Shawn Guertin CFO (57)
- Jonathan Roberts COO (65)
- Laurie Havanec CHO (60)
- Thomas Moriarty EVP (57)
- Troyen Brennan EVP (66)
- Daniel Finke EVP (50)
- Joshua Flum EVP (51)
- Alan Lotvin EVP (59)
- Neela Montgomery EVP (47)
- Michelle Peluso EVP (49)
- James Clark SVP (56)
- Prem Shah OTH
- Fernando Aguirre IND (64)
- C. David Brown IND (69)
- Alecia DeCoudreaux IND (66)
- Nancy-ann Deparle IND (64)
- Roger Farah IND (68)
- Anne Finucane IND (68)
- Edward Ludwig IND (69)
- Jean-Pierre Millon IND (70)
- Mary Schapiro IND (65)
- William Weldon IND (72)
- Tony White IND (74)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- August 22nd, 1996
- Public Since
- October 1st, 1952
- No. of Shareholders
- 23,098
- No. of Employees
- 300,000
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
New York Stock Exchange- Shares in Issue
- 1,260,480,127
- Address
- 1 Cvs Dr, WOONSOCKET, 02895-6146
- Web
- https://cvshealth.com/
- Phone
- +1 4017651500
- Contact
- Larry Mcgrath
- Auditors
- Ernst & Young LLP
Latest News for CVS
Upcoming Events for CVS
Dividend For CVS.BA - 0.0443 USD
Dividend For CVS.NLB - 0.1666 CAD
Dividend For CVSH34.SA - 0.3312 BRL
Dividend For CVS.N - 0.6650 USD
Q1 2024 CVS Health Corp Earnings Call
Q1 2024 CVS Health Corp Earnings Release
CVS Health Corp Annual Shareholders Meeting
CVS Health Corp Annual Shareholders Meeting
Q2 2024 CVS Health Corp Earnings Release
Similar to CVS
Agilon Health
New York Stock Exchange
AMERICAN WELL
New York Stock Exchange
AMN Healthcare Services
New York Stock Exchange
Ati Physical Therapy
New York Stock Exchange
Auna SAA
New York Stock Exchange
FAQ
As of Today at 19:06 UTC, shares in CVS Health are trading at $68.64. This share price information is delayed by 15 minutes.
Shares in CVS Health last closed at $68.64 and the price had moved by -8.99% over the past 365 days. In terms of relative price strength the CVS Health share price has underperformed the S&P500 Index by -26.5% over the past year.
The overall consensus recommendation for CVS Health is Buy. You can view the full broker recommendation list by unlocking its StockReport.
The CVS Health dividend yield is 3.84% based on the trailing twelve month period.
Last year, CVS Health paid a total dividend of $2.64, and it currently has a trailing dividend yield of 3.84%.Looking ahead, shares in CVS Health are due to go ex-dividend on 2024-04-19 and the next dividend pay date is 2024-05-01.
CVS Health are due to go ex-dividend on 2024-04-19 and the next dividend pay date is 2024-05-01. The historic dividend yield on CVS Health shares is currently 3.84%.
To buy shares in CVS Health you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $68.64, shares in CVS Health had a market capitalisation of $86.52bn.
Here are the trading details for CVS Health:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: CVS
Based on an overall assessment of its quality, value and momentum CVS Health is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in CVS Health is $87.30. That is 27.19% above the last closing price of $68.64.
Analysts covering CVS Health currently have a consensus Earnings Per Share (EPS) forecast of $8.30 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like CVS Health. Over the past six months, its share price has underperformed the S&P500 Index by -18.09%.
As of the last closing price of $68.64, shares in CVS Health were trading -5.63% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The CVS Health PE ratio based on its reported earnings over the past 12 months is 8.03. The shares last closed at $68.64.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
CVS Health's management team is headed by:
- David Dorman - NEC
- Karen Lynch - PRE
- Shawn Guertin - CFO
- Jonathan Roberts - COO
- Laurie Havanec - CHO
- Thomas Moriarty - EVP
- Troyen Brennan - EVP
- Daniel Finke - EVP
- Joshua Flum - EVP
- Alan Lotvin - EVP
- Neela Montgomery - EVP
- Michelle Peluso - EVP
- James Clark - SVP
- Prem Shah - OTH
- Fernando Aguirre - IND
- C. David Brown - IND
- Alecia DeCoudreaux - IND
- Nancy-ann Deparle - IND
- Roger Farah - IND
- Anne Finucane - IND
- Edward Ludwig - IND
- Jean-Pierre Millon - IND
- Mary Schapiro - IND
- William Weldon - IND
- Tony White - IND